April 24th 2024
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
December 19th 2023
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Exploring the Role of T-VEC in the Treatment of Metastatic Melanoma
February 28th 2018Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses a study exploring the role of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with metastatic melanoma.
Watch
Obesity Associated With Better Outcomes in Metastatic Melanoma
February 27th 2018Obese men treated with targeted or immune therapies for metastatic melanoma had a 47% reduced risk of death compared with men who had a normal BMI, according to results from a retrospective multicohort analysis published in <em>The Lancet Oncology.</em><br />
Read More
Expert Discusses Role of Mutation Status in Treatment Decisions for Melanoma
February 26th 2018Ryan J. Sullivan, MD, discusses the available therapies for patients with <em>BRAF-</em>mutant and non-<em>BRAF</em>-mutant melanoma, as well as the current role of mutation status in treatment decision making.<br />
Read More
Options for Patients With Melanoma Who Have Exhausted Standard Therapies
February 20th 2018Omid A. Hamid, MD, chief of Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses options for patients with melanoma who have exhausted standard therapies.
Watch
Updated Findings Show OS Improvement With Binimetinib/Encorafenib in Melanoma as FDA Decision Pends
February 19th 2018In findings from the phase III COLUMBUS trial, the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib improved survival versus single-agent vemurafenib (Zelboraf) in patients with <em>BRAF</em>-mutant advanced, unresectable or metastatic melanoma.
Read More
Promising Activity Seen from ERK1/2 Inhibitor in MAPK/ERK Mutations and BRAF/MEK Resistance
February 17th 2018Ulixertinib, a novel ERK1/2 inhibitor, demonstrated encouraging antitumor activity in patients with solid tumors harboring mutations in the MAPK/ERK pathway, according to the results of a phase I study published in <em>Cancer Discovery</em>.
Read More
National Academy of Science to Recognize Four Individuals for Cancer Breakthroughs
January 30th 2018During their 155th annual meeting, to be help April 29, the National Academy of Science (NAS) will award 19 individuals for their extraordinary scientific achievements in a wide range of fields including the physical, biological, and medical sciences.
Read More
The Evolving Role of Targeted Therapies in Melanoma
January 4th 2018Hussein A. Tawbi, MD, discusses the considerations he makes when choosing between immunotherapy and targeted therapy for patients with melanoma and how long-term targeted therapy data can influence treatment decisions.<br />
Read More
Expert Discusses Treatment Approaches, Research Needs for Patients With Extracutaneous Melanomas
January 4th 2018Richard D. Carvajal, MD, discusses considerations when diagnosing and treating extracutaneous melanomas and the importance of treating such diseases differently than the more commonly seen melanomas.
Read More
A Look Back at FDA News in the Month of December
January 3rd 2018The FDA closed out the year by approving several new agents last month, including bevacizumab for glioblastoma, cabozantinib for renal cell carcinoma, nivolumab for melanoma, bosutinib for chronic myeloid leukemia, and pertuzumab for HER2+ breast cancer. In addition, several agents were granted a priority review designation. Here is a look back at all the FDA activity that took place in December.
Read More
Current and Emerging Immunotherapeutic Strategies in Melanoma
January 3rd 2018Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses current and emerging immunotherapeutic strategies in melanoma.
Watch
Adjuvant Dabrafenib/Trametinib Granted Priority Review by FDA for BRAF+ Melanoma
December 22nd 2017Based on findings of the phase III COMBI-AD study, a supplemental new drug application for dabrafenib (Tafinlar) combined with trametinib (Mekinist) has been granted a priority review by the FDA as an adjuvant treatment for patients with <em>BRAF</em> V600E– or V600K–positive stage III melanoma following complete resection.
Read More
Expert Weighs in On Recent Adjuvant Therapy Data in Melanoma
December 21st 2017For patients with high-risk melanoma, the area of adjuvant treatment has seen little progress until recently. In large part, this is due to the lack of consensus in the community on what treatments to use, when to use them, and in which patients to implement them, explains Michael B. Atkins, MD.
Read More
Exciting Response Rates Seen in Updates Findings of bb2121 in Multiple Myeloma
December 13th 2017Chimeric antigen receptor T-cell therapy with bb2121 demonstrated an objective response rate of 94% in patients with relapsed/refractory multiple myeloma, according to findings from a dose-escalation study. The senior study author, James N. Kochenderfer, MD, presented updated findings from the study during the 2017 ASH Annual Meeting, and commented that 89% of patients had a very good partial response or better, and 56% of patients had a complete remission. <br />
Read More